Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
November 29, 2022 07:30 ET
|
Context Therapeutics Inc.
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December 1, 2022, at 11 a.m. ET PHILADELPHIA, Nov. 29,...
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
November 21, 2022 09:11 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and...
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
November 09, 2022 16:14 ET
|
Context Therapeutics Inc.
Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the...
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
September 27, 2022 07:30 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and...
Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:30 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and...
Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results
August 11, 2022 16:01 ET
|
Context Therapeutics Inc.
Announced new clinical trial collaboration with Menarini Group to evaluate ONA-XR plus elacestrant in metastatic breast cancer Results of the monotherapy portion of Phase 2 ONA-XR clinical trial...
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
August 02, 2022 07:30 ET
|
Context Therapeutics Inc.; The Menarini Group
Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and...
Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results
May 11, 2022 16:01 ET
|
Context Therapeutics Inc.
Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data...
Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
May 05, 2022 07:30 ET
|
Context Therapeutics Inc.
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary Trial advanced to second stage to...
Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 11, 2022 07:30 ET
|
Context Therapeutics Inc.
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First presentation of preclinical CLDN6xCD3 bispecific...